{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975668",
  "id": "02975668",
  "pages": 30,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdx0kbh3x5mq.pdf",
  "summary": "**Summary of AFT Pharmaceuticals 2025 Annual Shareholders' Meeting Announcement**  \n\n### **Financial & Operational Highlights**  \n- **FY25 Revenue**: NZ$208.0M (6% YoY growth), with ANZ sales at NZ$180.9M.  \n- **FY27 Target**: Revenue of NZ$300M.  \n- **Operating Profit**: NZ$17.6M (down from NZ$24.2M in FY24 due to lower licensing income and strategic investments).  \n- **Dividend**: Increased to 1.8 cents per share (from 1.6 cps in FY24).  \n- **Net Debt**: NZ$14.5M (down from NZ$16.2M in FY24).  \n- **R&D Spend**: NZ$15.0M (FY25), focused on 8 patented products and 24+ injectables.  \n\n### **Market Expansion & Strategy**  \n- **Global Reach**: Products sold in ~80 countries; distribution agreements in 100+ countries.  \n- **Key Markets**: Growth in Australasia (NZ: NZ$53.8M; Australia: NZ$127.1M), hampered by disruptions in Asia (NZ$15.4M, down from NZ$19.3M).  \n- **New Hubs**: Launches in EU, UK, USA, Canada, South Africa, Hong Kong, and Singapore, with pipelines of 17\u201340 products per region.  \n\n### **R&D Pipeline Highlights**  \n- **Near-Term**: 24 hospital injectables (filing 2025\u20132027), Migraine project (filing 1Q27), Pascomer (PWS treatment, filing 2027).  \n- **Long-Term**: Antibiotic eye drop (2028), Keloid scar topical (2029), Burning Mouth Syndrome (2030).  \n\n### **Governance Resolutions**  \n1. Auditor remuneration approval (Deloitte).  \n2. Re-election of Dr. Hartley Atkinson as Director.  \n3. Election of Allison Yorston as Director.  \n\n### **Outlook**  \n- **FY26 Operating Profit Guidance**: NZ$20M\u2013NZ$24M.  \n- Focus on product launches, international growth, and R&D commercialization.  \n\n**Omitted**: Director names, boilerplate, historical background, and non-material operational details.",
  "usage": {
    "prompt_tokens": 5861,
    "completion_tokens": 491,
    "total_tokens": 6352,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T21:46:35.883463"
}